Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/49886
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHernández, José Luis-
dc.contributor.authorPadilla, Laura-
dc.contributor.authorDakhel, Sheila-
dc.contributor.authorColl, Toni-
dc.contributor.authorHervas, Rosa-
dc.contributor.authorAdan, Jaume-
dc.contributor.authorMasa, Marc-
dc.contributor.authorMitjans, Francesc-
dc.contributor.authorMartínez, Josep Maria-
dc.contributor.authorComa i Bassas, Sílvia-
dc.contributor.authorRodríguez Gallego, Laura-
dc.contributor.authorNoé Mata, Verónica-
dc.contributor.authorCiudad i Gómez, Carlos Julián-
dc.contributor.authorBlasco, Francesc-
dc.contributor.authorMesseguer i Peypoch, Ramon-
dc.date.accessioned2014-02-13T16:43:33Z-
dc.date.available2014-02-13T16:43:33Z-
dc.date.issued2013-09-04-
dc.identifier.issn1932-6203-
dc.identifier.urihttp://hdl.handle.net/2445/49886-
dc.description.abstractS100A4, a member of the S100 calcium-binding protein family secreted by tumor and stromal cells, supports tumorigenesis by stimulating angiogenesis. We demonstrated that S100A4 synergizes with vascular endothelial growth factor (VEGF), via the RAGE receptor, in promoting endothelial cell migration by increasing KDR expression and MMP-9 activity. In vivo overexpression of S100A4 led to a significant increase in tumor growth and vascularization in a human melanoma xenograft M21 model. Conversely, when silencing S100A4 by shRNA technology, a dramatic decrease in tumor development of the pancreatic MiaPACA-2 cell line was observed. Based on these results we developed 5C3, a neutralizing monoclonal antibody against S100A4. This antibody abolished endothelial cell migration, tumor growth and angiogenesis in immunodeficient mouse xenograft models of MiaPACA-2 and M21-S100A4 cells. It is concluded that extracellular S100A4 inhibition is an attractive approach for the treatment of human cancer.-
dc.format.extent17 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherPublic Library of Science (PLoS)-
dc.relation.isformatofReproducció del document publicat a: http://dx.doi.org/10.1371/journal.pone.0072480-
dc.relation.ispartofPLoS One, 2013, vol. 8, num. 9, p. e72480-
dc.relation.urihttp://dx.doi.org/10.1371/journal.pone.0072480-
dc.rightscc-by (c) Hernández, José Luis et al., 2013-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es-
dc.subject.classificationCàncer-
dc.subject.classificationProteïnes de la sang-
dc.subject.classificationAngiogènesi-
dc.subject.classificationAnticossos monoclonals-
dc.subject.otherCancer-
dc.subject.otherBlood proteins-
dc.subject.otherNeovascularization-
dc.subject.otherMonoclonal antibodies-
dc.titleTherapeutic targeting of tumor growth and angiogenesis with a novel anti-S100A4 monoclonal antibody-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec628843-
dc.date.updated2014-02-13T16:43:33Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
Appears in Collections:Articles publicats en revistes (Bioquímica i Biomedicina Molecular)

Files in This Item:
File Description SizeFormat 
628843.pdf1.89 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons